Clinical trial
The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not…
NCT00441584 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00441584 |
|---|---|
| Title | The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833) |
| Official title | Efficacy and Safety of PEG-Intron Plus Rebetol in Subjects With Chronic Hepatitis C Genotype 1 Non Responder to Pegasys |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | Integrated Therapeutics Group Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Biological, Drug |
| Interventions | PegIntron (peginterferon alfa-2b), Rebetol (ribavirin) |
| Enrollment | 117 |
| Start date | Jul 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Mar 1, 2007 |
| Last update posted | Apr 5, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: